EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57

Abstract

IMMUNOMODULATORY EFFECT OF ASHWAGANDHA AGAINST DOXORUBICIN TOXICITY

Tarique Faizi Rizvi, Md. Razauddin, Md. Saif URRahman, Talat Jahan, Zeba Naz, Ranjit Kumar, Arun Kumar and Mohammad Ali*

ABSTRACT

Doxorubicin is a member of the Anthracyclin drug family and one of the most frequently used drug to treat many forms of cancer such as leukemia, lymphoma and solid tumors. Doxorubicin is an essential component of treatment for childhood solid tumors and aggressive lymphomas and shows activity in acute lymphoblastic or myeloblastic leukemias. The use of the drug induced cardio toxicity and affects the immune functions. This toxic side effect makes the problem during cancer chemotherapy causes myelosuppression, mucosal ulceration, alopecia and diarrhoea etc. The aim of the study was to evaluate therapeutic impact of Ashwagandha for ameliorating the toxic side effects being produced during doxorubicin administration. In the present investigation aqueous root extract of Ashwagandha @ 300 mg/kg b.w. was used against administration of doxorubicin @ 5 mg/kg b.w. in rats. White Blood Cell count, Platelets and Absolute Lymphocyte Count were observed for immune function. A marked reduction in total count of WBC, ALC and Platelets were observed on day 5th however slight reduction in the above counts were also observedday 21st .and elevated level of Lipid Peroxidaion was observed on day 21st. When Ashwagandha @ 300 mg/kg b.w. administered five days prior to Doxorubicin administration and continued for 21 days, then significant increase in total count of WBC, ALC and Platelets were observed through out the cycle. Level of lipid Peroxidaion was also declined towards normal during cycle. Thus findings of present investigation showed that therapeutic potency of Ashwagandha ameliorate the toxicity produced during cancer chemotherapy.

Keywords: Ashwagandha, Doxorubicin, White Blood Cell Count, Absolute Lymphocyte Count, Platelets and LPO.


[Full Text Article] [Download Certificate]

Citation

  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44

INDEXING

NEWS & UPDATION

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 November 2024 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

  • EJPMR: NOVEMBER ISSUE PUBLISHED

    NOVEMBER 2024 issue has been successfully launched on NOVEMBER 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along witcertificate to promote resear activity of scholar.

Best Article of current issue :

Dr. Kartik Neog
Download Article : Click here